Galderma Group N (GALD SW) stock market data APIs
CHF194.8652
-5.69(-2.9%)
as of November 11, 2026
Try our APIs with
free plan!
Galderma Group N Financial Data Overview
Price chart is built with
Anychart
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Prev. Close
194.8652
Open
189.1779
High
195.6624
Low
185.9918
52 wk Range
136.0031-196.8
Market Cap
45 460 M
P/E Ratio
64.9833
Shares Outstanding
233 M
Revenue
5 923 M
Dividends (Yield)
0.0023
Beta
-0.108
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Galderma Group N (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Galderma Group N data using free add-ons & libraries
Get Galderma Group N Fundamental Data
Galderma Group N Fundamental data includes:
- Net Revenue: 5 923 M
- EBITDA: 1 386 M
- Earnings Per Share: 3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-06-30
- EPS/Forecast: 1.27
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galderma Group N News
New
Galderma Announces Proposed Board Appointments and Chief Financial Officer Transition
The Company will hold an Extraordinary General Meeting on December 3, 2026 to further reinforce its Board of Directors Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland, November 02, 2026-...
Galderma (SWX:GALD) Stock Could Be 39% Undervalued Following China Approval
Galderma Group has delivered a strong share price run over the past year, and the recent flow of product and deal news keeps the story in the headlines. The open question is whether the current market...
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improv...
Galderma raises 2026 sales growth outlook after Q3 revenue beats forecasts
Investing.com -- Swiss dermatology group Galderma raised its 2026 sales growth guidance on Thursday after third-quarter growth of 26% at constant currency beat analyst expectations, though it kept its...
Get Galderma Group N fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.